BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update
BioNTech reported Q2 2026 revenue of €105.6 million, down from €260.8 million a year ago, and narrowed its full-year revenue guidance to €1.6–1.9 billion from €2.0–2.3 billion due to softer COVID-19 demand and milestone timing. The company posted a net loss of €820.8 million but maintained a strong balance sheet with €16.6 billion in cash and equivalents. The company announced a leadership transition, appointing Guido Oelkers, Ph.D., as the new CEO effective by February 2027, succeeding Prof. Ugur Sahin.
Key figures
- Revenue
- 105600000
- Guidance
- FY26 revenue €1.6–1.9 billion (revised from €2.0–2.3 billion); Adj R&D €2.0–2.3 billion; Adj SG&A €700–800 million
- Cash position
- €16.6 billion
- Buyback spend q2
- $151.6 million
- Buyback authorization
- $1.0 billion
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.